USA flag logo/image

An Official Website of the United States Government

Artificial Cornea Using New Biomaterials

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93783
Program Year/Program:
2009 / STTR
Agency Tracking Number:
EY019795
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
HEALIONICS CORPORATION
2121 N 35th St SEATTLE, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Artificial Cornea Using New Biomaterials
Agency: HHS
Contract: 1R41EY019795-01
Award Amount: $116,418.00
 

Abstract:

DESCRIPTION (provided by applicant): Artificial Cornea Using New Biomaterials PD/PI Maxwell Maginness PhD Project Summary/Abstract. We propose to advance the development of a novel artificial cornea design enabled by a new biomaterial technology permitting facile integration and sclera tissue reconstruction. The design offers potential for an excellent visual outcome, stable and robust integration with the host tissue; is anticipated to overcome limitations of previous artificial cornea designs and does not require human donor tissue. Early animal studies also suggest that the design allows for a simple surgical implantation technique. The proposal is directed at the National Eye Institute Corneal Diseases Program under the development of new biomaterials f or corneal prostheses listing. The Medical Problem: Corneal blindness opacification of the transparent tissue covering the front of the eye is one of the two most prevalent causes of treatable blindness. It affects some 12 million people worldwide. [1] Co rneal transplants with human donor tissue offer solutions for a fraction of patients with less severe disease, with approximately 100,000 such procedures worldwide every year. These procedures require the support of eye banks, not available in many world r egions with a high incidence of blindness. In developed countries increasing numbers of LASIK procedures are rendering many potential donor eyes unusable. [2] The alternative is an artificial cornea (Keratoprothesis K-pro ). There are two currently availa ble FDA- approved devices - the Boston K-Pro [3] and the AlphaCor device [4]. These show poor integration with host tissue and require complex surgical implantation with lengthy follow-up. Presently they are offered only as a last resort in a few centers n ationwide (University of Washington is one of them), leaving many untreated cases. Proposed Solution: Our proposed artificial cornea design aims to overcome these limitations a by combining: A clear, semi rigid optical center, proven to provide excellent a nd rapid visual recovery A porous periphery based on Spherically Templated Angiogenic Regenerative (STAR) biomaterial structure to rapidly achieve a robust, stable, well-integrated host tissue interface. Use of well proven biocompatible materials (silicone s) with appropriate optical and mechanical properties for the entire artificial cornea device structure. No donor tissue required. Simple, one step surgical procedure. Originally developed at the University of Washington Engineered Biomaterials Laboratory under Dr Buddy Ratner, (mentoring this project) STAR [5] is a porous 3D biomaterial with a unique, tightly controlled geometry enhancing tissue attachment, in-growth and revascularization. The structure may be made from a variety of substrate materials, in cluding biocompatible silicone rubbers as already widely used in other ophthalmic devices (e.g. glaucoma shunts, IOL's). Healionics Corporation holds exclusive license and is commercializing forms of the STAR material for a variety of medical applications. Preliminary studies with STAR biomaterial structures in the rabbit sclera have shown the rapid tissue integration and desirable reconstructive, vascularized, afibrotic healing patterns needed for a successful prosthetic cornea. The primary aim of this pro posal is to extend and combine the biomaterials capability of Healionics Corporation with the in vitro and in vivo feasibility studies done by Dr. Ratner and Dr. Shen of UW Ophthalmology towards the next steps in developing an artificial cornea. The propos ed developments of better construction methods, periphery tissue adhesion studies, durability testing and an extension of in vivo studies, are directed to this goal. The longer term aim is to refine the designs in the light of results obtained under this p roposal, proceed to a more extensive study and eventually to human use. Keywords: Artificial cornea, porous biomaterials, treatable blindness, corneal transplant surgery. PUBLIC HEALTH RELEVANCE: Corneal opacity is a major cause of blindness. Use of donor corneas is not applicable for many cases and artificial corneas developed to date have shown serious limitations. The development of a new biomaterial structure with greatly improved sclera tissue integration and excellent optics shows potential to overco me many of these issues and allow construction and application of an improved prosthesis. Success with the steps proposed here may lead eventually to sight restoration covering a much wider population than is possible with present methods.

Principal Investigator:

Max Maginness

Business Contact:

Maxwell Maginness
maxm@healionics.com
Small Business Information at Submission:

HEALIONICS CORPORATION
HEALIONICS CORPORATION 14787 NE 95TH ST REDMOND, WA 98052

EIN/Tax ID: 120859315
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF WASHINGTON
UNIVERSITY OF WASHINGTON
Office of Sponsored Programs
SEATTLE, WA 98195 9472
RI Type: Nonprofit college or university